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Abstract
Psoriasis is associated with increased cardiovascular disease (CVD) in adults, but the risk profile 
of children with psoriasis remains to be fully characterized. We measured lipoprotein composition 
and function in 44 pediatric psoriasis patients and 44 age- and sex-matched healthy controls, using 
NMR spectroscopy and a validated ex vivo assay of high density lipoprotein (HDL) cholesterol 
efflux capacity (CEC). Mean age was 13.0 years and the population was ethnically diverse. 
Children with psoriasis had higher waist-hip ratios (0.85 vs. 0.80; p<0.002) and insulin resistance 
measures (log transformed HOMA-IR 0.65 vs. 0.41; p=0.07). Despite comparable traditional lipid 
values, having psoriasis was associated with higher apolipoprotein B concentrations (72.4 vs. 
64.6; p=0.02), decreased large HDL particles (5.3 vs. 6.7; p<0.01), and reduced CEC after 
adjusting for age, sex, fasting glucose, HOMA-IR, systolic blood pressure, body mass index, 
apolipoprotein A-1, and HDL cholesterol concentration (beta -0.22, p=0.02). Pediatric psoriasis 
patients have a more atherogenic cardiometabolic risk profile, with evidence of insulin resistance 
and lipoprotein dysfunction by particle size, number, and functional assessment. These findings 
may provide a basis for the observed link later in life between psoriasis and CVD and support the 
need to screen and educate young patients to minimize later complications.
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Introduction
Psoriasis is a chronic, immune-mediated skin disorder with an established association with 
increased metabolic and cardiovascular disease (CVD) risk in adults (Armstrong et al., 
2013; Langan et al., 2012; Samarasekera et al., 2013). Mechanisms linking these conditions 
remain to be fully understood, but systemic inflammation in psoriasis appears to predispose 
to abnormalities that include a pro-atherogenic lipoprotein profile, large vessel 
inflammation, and adipokine dysregulation (Li et al., 2014; Mehta et al., 2012; Mehta et al., 
2011; Rajappa et al., 2015). As psoriatic disease begins in childhood in approximately one-
third of cases, the potential for early impairment is of interest. Several studies have 
demonstrated that obesity, insulin resistance, and dyslipidemia are present at higher rates in 
affected children (Augustin et al., 2010; Ferretti et al., 1993; Koebnick et al., 2011; Paller et 
al., 2013; Torres et al., 2014), but additional study is needed on the timing, magnitude, and 
factors influencing and underlying such dysfunction.
To further characterize cardiometabolic risk in affected children, detailed lipoprotein 
characterization was performed with comparison to healthy controls. Beyond traditional 
lipid concentration, nuclear magnetic resonance (NMR) spectroscopy can accurately detect 
lipoprotein particle composition, size, and number (Otvos et al., 1992). In particular, this 
includes low density lipoprotein (LDL) particle concentration (LDL-p), which has recently 
been shown to be a superior marker of CVD risk to LDL cholesterol concentration (LDL-c), 
particularly when the two values are discordant (Cromwell et al., 2007; Otvos et al., 2011; 
Rizzo et al., 2013). High density lipoprotein (HDL) particle composition and size can also 
be assessed, which have been shown to be altered and related to vascular inflammation in 
adult psoriasis (Holzer et al., 2012; Yu et al., 2012).
A key function of HDL is transportation of cholesterol from peripheral tissues, such as the 
arterial wall, to the liver for excretion into the bile. We and others have utilized a reliable 
assay to estimate this important property of HDL-promoted cholesterol efflux capacity 
(CEC), which may be more significant than traditional HDL cholesterol concentration 
(HDL-c) in predicting risk of CVD (Khera et al., 2011; Khera and Rader, 2013; Rohatgi et 
al., 2014). These advanced measures of lipoprotein composition and function may be useful 
for early detection of cardiometabolic aberrations in the pediatric population, where changes 
are likely to be more subtle. We hypothesized that psoriasis in children would promote a 
more atherogenic pattern, consisting of an elevated apolipoprotein B-100 (apo B) level, 
increased number of smaller LDL particles, a reduction in larger HDL particles, and reduced 
CEC after adjusting for known risk factors for CVD.
Results
Subjects were 13.0 +/- 4.3 years of age (mean +/- standard deviation, unless otherwise 
noted), with near equal percentage of the two sexes (additional demographics in Table 1). 
Psoriasis subjects had involvement of 15.7 +/- 3.3 percent body surface area (% BSA; mean 
+/- standard error), with 25% having mild, 36% moderate, and 39% severe disease based on 
BSA. Mean duration of psoriasis was 5 +/- 4 years. Body mass index (BMI) was 23.5 +/- 6.1 
kg/m2, with 20% being overweight (BMI between 85th and 94th percentile, inclusive) and 
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27% being obese (BMI ≥95th percentile). One psoriasis subject had rheumatologist-
confirmed psoriatic arthritis, one had polycystic ovarian syndrome, and a third had 
diagnosed hypertension on drug therapy. None were on lipid-lowering agents. Forty-five 
percent had a positive family history of psoriasis. Controls had significantly lower BMI 
values (21.4 +/- 4.3 kg/m2; p=0.03), with 16% being overweight and only 9% obese, along 
with a lower waist to hip ratio. Smoking and alcohol history were not significantly different 
between the two groups (one current smoker in each, one case and 3 controls reported 
occasional alcohol intake). The psoriasis group also had a significantly higher incidence of 
hypertension, type 2 diabetes, dyslipidemia and coronary artery disease in the family.
Children with psoriasis demonstrated a trend toward higher homeostasis model assessment 
of insulin resistance (HOMA-IR) values (2.41 vs. 1.99; p=0.11), which was more apparent 
after log-transformation of HOMA-IR to fit the Gaussian distribution (0.65 vs. 0.41; 
p=0.07). BMI was the strongest predictor of HOMA-IR (beta 0.49, p <0.001 compared to 
beta 0.13, p=0.05 for presence of psoriasis and beta 0.29, p<0.01 for waist to hip ratio) in 
unadjusted regression analyses and on adjustment for age, sex, glucose, systolic blood 
pressure, and HDL-c. Four of the psoriasis patients had elevated C-reactive protein (CRP) 
levels, while no controls had abnormal values (p=0.02); these 4 psoriasis subjects were also 
overweight or obese. Traditional lipid concentrations were not significantly different 
between children with psoriasis and controls and NMR-measured LDL particle 
concentration (LDL-p) and size (LDL-z) also did not differ (Table 2). Serum apo B levels, 
however, were increased in the psoriatic group (72.4 +/- 18.1 vs. 64.6 +/- 16.2; p=0.02). 
HDL particles tended to be smaller in general (p=0.02), and the number of large HDL 
particles was decreased in those with skin disease (5.3 +/- 2.9 vs. 6.7 +/- 2.5; p<0.01). The 
same findings were noted on exclusion of the two psoriasis subjects on systemic therapy and 
on analysis of plaque type disease alone and guttate and other mixed types alone, compared 
to their respective controls (data not shown). While increased very low density lipoprotein 
(VLDL) particle size was mainly noted in overweight and/or obese psoriasis subjects, the 
trend toward smaller HDL particles and decreased number of large HDL particles became 
significant only when the normal BMI group was added in addition to the overweight and 
obese groups. Moreover, apo B levels were elevated even in normal BMI cases compared 
with their controls (75.4 ± 20.4 vs. 64.2 ±17.5, p=0.02). Psoriasis subjects with a positive 
family history of type 2 diabetes had increased number of small and total LDL particles 
relative to those without such family history (p=0.002 and p=0.04, respectively; see Table 
S2).
A full list of correlations of cholesterol efflux capacity with all cardiometabolic parameters 
can be found in Supplemental Table 1. As noted in prior studies, HDL-c and apolipoprotein 
A-1 (apo A-1) levels were strong predictors of efflux capacity (p<0.001 for both), while 
higher BMI, waist circumference, and HOMA-IR were associated with decreased efflux. In 
unadjusted analyses, CEC was found to be significantly different between the psoriasis 
group and controls (0.90 +/-0.15 vs. 0.95 +/- 0.12; p = 0.02), and this decrease in efflux in 
children with psoriasis remained after adjusting for age, sex, fasting glucose, HOMA-IR, 
systolic blood pressure, BMI, apo A-1, and HDL-c (beta -0.22, p=0.021; Table 3). These 
primary estimates did not change when children currently undergoing systemic therapy for 
psoriasis, including those receiving biologic agents, were excluded. Presence of psoriasis 
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had greater effect on efflux capacity than having a BMI percentile in the overweight and/or 
obese range (χ2= 9.12, p =0.003; Table 4). Those with 5% BSA or greater involvement or 
Psoriasis Area and Severity Index (PASI) scores 6 or greater showed decreased efflux 
capacity compared to those with less skin involvement (p=0.02 and p=0.02, respectively; see 
Figure 1a and 1b). CEC grouped by mild, moderate, and severe skin disease is depicted in 
Figure S1. Stratified analysis did not demonstrate any ethnic differences in efflux capacity 
within the psoriasis group (p=0.19), nor any differences based on family history of psoriasis 
(p=0.10), coronary heart disease (p=0.66), hypertension (p=0.76), or dyslipidemia (p=0.89) 
(Table S3). However, children with psoriasis and a positive family history of type 2 diabetes 
mellitus had significantly lower CEC measurements when compared to those with no such 
family history (0.83 +/- 0.11 vs. 0.96 +/- 0.15, p=0.001; Table S2). Likelihood ratio testing 
to understand which NMR-estimate HDL parameters best predicted efflux capacity showed 
that HDL particle size (HDL-z), particle concentration (HDL-p), and cholesterol 
concentration (HDL-c) were all important factors, but HDL-z had the largest effect of the 
three (χ2=19.72, p <0.0001; Table 5).
Discussion
Here we provide, to our knowledge, previously unreported advanced lipoprotein 
compositional and functional assessments in pediatric psoriasis subjects. Our findings 
demonstrate an adverse cardiometabolic risk profile even in the early years of skin disease, 
with a tendency toward increased insulin resistance, a more atherogenic lipoprotein particle 
profile, and lipoprotein dysfunction as assessed by cholesterol efflux, compared to non-
psoriatic controls.
Systemic inflammation has been tied to insulin resistance in murine and human studies, with 
worsening of both as BMI increases (Esser et al., 2014; Li et al., 2011). Our pediatric 
psoriasis subjects showed such clustering of inflammation (measured by CRP), overweight 
and obesity, and greater insulin resistance as estimated by log transformed HOMA-IR. 
HOMA-IR was used given strong correlation with the gold standard hyperinsulinemic 
euglycemic clamp technique and easier performance in young children (Henderson et al., 
2011). In multivariate regression analyses, BMI was by far the strongest predictor of 
HOMA-IR, but presence of psoriasis and waist to hip ratio also had some effect. Adult 
studies have also noted insulin resistance even in non-obese patients with psoriasis (Ucak et 
al., 2006). Using the euglycemic clamp technique, Gyldenlove et al. found that in normal 
glucose-tolerant adults, moderate to severe psoriasis subjects demonstrated greater insulin 
resistance than healthy controls of comparable BMI and body composition (Gyldenlove et 
al., 2015).
Decreasing calculated or measured LDL cholesterol concentration has for many years been 
the major goal of lipid-modulating therapies, yet a significant number of CVD-related events 
occur despite having traditional LDL-c at optimal levels (Cromwell et al., 2007). Studies 
have shown direct quantification of lipoprotein particles to be more sensitive than LDL-c in 
identifying future cardiometabolic risk, particularly in chronic conditions with low-grade 
inflammation such as metabolic syndrome and type 2 diabetes mellitus (Cromwell and 
Otvos, 2006; Otvos et al., 2011; Rosenson et al., 2010). Consistent with this observation, we 
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found no difference in LDL-c estimates in our pediatric psoriasis cohort but observed an 
elevation in a more sensitive metric, apo-B levels. The apo-B concentration corresponds to 
the total number of atherogenic lipoprotein particles, including VLDL, intermediate density 
lipoprotein (IDL), and LDL. On the other hand, no significant differences were found in 
either LDL particle concentration or size in our subjects relative to controls. This is in 
contrast to our adult psoriasis study, where these parameters were negatively altered, despite 
more psoriasis patients being on lipid-lowering therapy (Mehta et al., 2012). LDL particle 
measurements are influenced by traditional CVD risk factors, such as hypertension, 
dyslipidemia (as measured by traditional lipids), and tobacco use, which were present in the 
adult psoriasis cohort with increased frequency. These disorders, however, were not yet 
prominent in our much younger population, where there was mainly excess adiposity but 
minimal overt clinical disease. These findings suggest that LDL-p may take longer duration 
of exposure to cardiometabolic diseases to manifest differentially.
Additional tendency toward an atherogenic profile was noted on examining HDL 
composition in our pediatric subjects. There was a trend toward smaller HDL particle size, 
and fewer large, HDL particles, similar to the pattern seen in adult psoriasis (Yu et al., 
2012). Such profiles have been noted to correlate with coronary atherosclerosis (Arsenault et 
al., 2009; El Harchaoui et al., 2009). Lower lecithin-cholesterol acyltransferase (LCAT) 
activity may contribute to the smaller HDL particle size and distribution measured. LCAT is 
a key enzyme in HDL metabolism and mediates cholesterol esterification, resulting in their 
partitioning into the core of the HDL particle which increases particle size. Effective therapy 
for psoriasis has been demonstrated to increase LCAT activity (Holzer et al., 2014). 
Moreover, vascular inflammation in adult psoriasis has been observed to be associated with 
these HDL particle changes, as assessed by measuring macrophage activity in 
atherosclerotic plaques of large vessels using [18F]-fluoro-deoxyglucose-positron emission 
tomography (Yu et al., 2012). Our study findings suggest that HDL particle size may 
capture early cardiometabolic effects with greater sensitivity than traditional lipid metrics.
Although traditional HDL cholesterol levels are inversely correlated with CVD events, 
therapies increasing HDL-c have not shown substantial effect in decreasing their risk, 
sparking the concept that HDL function is more important to disease outcome than the 
quantity of HDL (Barter et al., 2007; Khera et al., 2013; Rohatgi et al., 2014). An important 
anti-atherogenic function of HDL is “reverse cholesterol transport,” whereby HDL particles 
accept cholesterol from lipid-laden macrophages, such as those within atherosclerotic 
plaques, for transport and eventual biliary excretion. Ex vivo measurement of cholesterol 
efflux capacity using apoB-depleted serum from subjects assesses this property and has been 
demonstrated in two distinct cohorts to be more influential than HDL-c or apo A-1 levels in 
predicting atherosclerotic burden and the incidence of CVD events (Khera et al., 2011; 
Khera and Rader, 2013; Rohatgi et al., 2014). Efflux from macrophages and other aspects of 
HDL function, such as the anti-oxidative activity of HDL-associated paraoxonase protein, 
have been shown to be impaired in adults with psoriasis, with improvement in function with 
effective topical or systemic psoriasis therapy (Holzer et al., 2014; Marsche et al., 2014; 
Mehta et al., 2012). In our study, children with psoriasis had significantly decreased CEC 
relative to healthy matched controls before and after adjusting for confounding variables, 
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suggesting that reverse cholesterol transport defects start early in life even with very low 
levels of chronic inflammation. Psoriatic disease had greater impact on HDL function than 
did elevated BMI levels. This provides further evidence of independent negative effects of 
psoriasis on lipoprotein function and associated unfavorable cardiometabolic risk. More 
severe skin disease also correlated with greater impairment of CEC, which is in line with 
other studies that have shown increased metabolic abnormalities with greater psoriasis 
severity scores (Armstrong et al., 2013; Langan et al., 2012).
In our study, children with psoriasis and normal BMI appeared to have an atherogenic 
profile even if on a lesser scale, including having elevated apo B levels compared to their 
normal BMI controls and a trend toward decreased large HDL particle number and HDL 
size. In addition, our data suggested that aberrations may not be unique to only plaque 
psoriasis, which is an important finding.
Use of NMR spectroscopy provides reliable and more detailed lipoprotein phenotyping 
beyond traditional lipid concentration. A main goal of our study was to understand how 
these more sensitive parameters may detect abnormalities earlier in the pediatric population. 
In fact, the characterization of lipoprotein particle composition demonstrated that HDL 
features were different between psoriasis and healthy controls even at this young age. Our 
study also demonstrated that CEC may be best predicted by HDL particle size, and given the 
labor involved in assays of cholesterol efflux, NMR spectroscopy may in fact identify 
multiple features of lipoprotein dysfunction. The use of particle number and size may 
therefore augment our detection of aberrations in this population at high risk for 
dyslipidemia in later life.
Overall, our findings support the concept that psoriasis, a condition characterized by a low-
level systemic inflammatory state, predisposes to a more atherogenic profile early in the 
course of disease, and that outcomes which have been well studied in adults, such as obesity, 
diabetes, and atherosclerotic disease, may start early with precursor changes. This highlights 
the need to educate physicians (primary care and dermatologists), patients, and families 
alike regarding these co-morbid conditions and potential future risks and to periodically 
assess young psoriasis patients for cardiometabolic risk. While screening guidelines have 
existed for adult psoriasis patients for several years, comparable recommendations are only 
now in development for children.
Our study was limited by a relatively small sample size; however, this is the largest 
undertaking in pediatric psoriasis lipoprotein characterization to date. Furthermore, since 
this was a cross-sectional study, a cause and effect relationship between psoriasis and 
measured aberrations cannot be proven. A positive family history of type 2 diabetes showed 
correlation with lipoprotein abnormalities noted in psoriatic subjects, including increased 
number of small LDL particles, fewer large HDL particles, and decreased cholesterol efflux 
capacity, and it may therefore itself contribute to risk, or it may serve as a marker for other 
factors at play (e.g. polymorphic variants of the apo genes). Other potential confounders to 
address with additional research include ethnic background, effects of previous treatments, 
and more detailed lifestyle habits including activity and diet. Ongoing prospective studies 
will better inform a potential temporal relationship.
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In conclusion, we demonstrate that there is systemic inflammation, obesity, and a pattern 
toward insulin resistance, lipoprotein composition abnormalities, and lipoprotein functional 
modulation in pediatric psoriasis. Studying a larger cohort of children with assessment of 
cholesterol transport pathways can give insight to underlying pathogenesis, while 
comparison with affected adults can delineate the impact of disease duration. Further 
understanding the mechanisms linking these co-morbidities to skin disease (e.g. shared 
signaling pathways, shared proinflammatory cytokines and adipokines), stratifying patients 
by risk, and early counseling on lifestyle and other modifications can aid in mitigation of 
their effects. Future studies should also evaluate whether more vigilant psoriasis therapy will 
lead to improved cardiometabolic health.
Materials and Methods
The study complied with the Declaration of Helsinki protocols and was approved by the 
University of California, San Diego Institutional Review Board. Written informed consent 
was obtained from all subjects. Forty-four children and adolescents, age 0 to 18 years, with 
active psoriasis and 44 age- and sex-matched healthy controls were enrolled at a 
dermatology clinic. All races, ethnicities, and psoriasis types (with or without psoriatic 
arthritis) were allowed, with diagnosis clinically confirmed as typical psoriasis by a 
dermatologist or pediatric dermatologist. Subjects could not have a diagnosis of congenital 
heart disease; any prior cardiac catheterizations or surgeries; have taken any cardiac 
medications (calcium channel blockers, beta blockers, vasotropic medicines) within the past 
2 years, other than for hypertension; have other systemic inflammatory disease (including 
active atopic dermatitis, severe acne, inflammatory bowel disease, juvenile idiopathic 
arthritis, and connective tissue/autoimmune disease); or have active infection or malignancy. 
In addition, control subjects could not have a personal or first-degree family history of 
psoriasis, and they usually presented for evaluation of nevi, birthmarks, warts, or 
molluscum. Subjects in both groups were consecutively recruited in order to minimize 
ascertainment bias.
Psoriasis subjects were examined and the % BSA involvement and Psoriasis Area and 
Severity Index (PASI) score determined. Anthropometric, BMI, and blood pressure 
measurements were obtained on all subjects and venous blood samples collected after at 
least 10 hours of fasting. We utilized auto-analyzers to measure serum insulin, glucose, and 
traditional lipid concentrations, and automated turbidimetric immunoassays for 
apolipoprotein A-1 and B concentrations (Mayo Medical Laboratories, Rochester, MN). 
LDL cholesterol concentration (LDL-c) was generated using the Friedwald formula. The 
homeostasis model assessment of insulin resistance (HOMA-IR) index was used to estimate 
the degree of insulin resistance [HOMA-IR = fasting glucose (mg/dl) * fasting insulin (mU/
ml) / 405)]. C-reactive protein was measured as a marker of systemic inflammation.
Ethylenediaminetetraacetic acid was used as the anticoagulant. Lipoprotein particle 
concentration and diameters were measured using automated NMR spectroscopy 
(LipoScience Inc., Raleigh, NC). Cholesterol efflux capacity (CEC) was determined as per 
previously published methods (Khera et al., 2011; Mehta et al., 2012), with slight 
modifications. J774 cells derived from a murine macrophage cell line were plated and 
Tom et al. Page 7
J Invest Dermatol. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
radiolabeled with 2 microcuries (μCi) of 3H-cholesterol/mL. ATP-binding cassette 
transporter A1 (ABCA1) was up-regulated by means of a 6-hour incubation with 0.3 
mmol/L 8-(4-chlorophenylthio)-cAMP. Subsequently, efflux mediums containing 2.8% apo 
B-depleted serum from study subjects (prepared as per Mehta et al., 2012) were added for 4 
hours. The efflux of radioactive cholesterol from the cells was quantified using liquid 
scintillation counting. Efflux was calculated by using the following formula: [(μCi of 3H-
cholesterol in media containing 2.8% apoB-depleted subject serum – μCi of 3H-cholesterol 
in serum-free media) ÷ (μCi of 3H-cholesterol in media containing 2.8% apoB-depleted 
pooled control serum – μCi of 3H-cholesterol in serum-free media). The pooled serum was 
obtained from five healthy volunteers and run on each plate in duplicates. All assays were 
performed in duplicate and the mean coefficient of variation of this assay in psoriasis 
subjects was 4.3% and in controls 3.3%.
Normality was assessed by skewness and kurtosis. Normally distributed continuous 
variables were compared using student's t-test, while those lacking a normal distribution 
were compared using the Mann–Whitney U test. Dichotomous variable comparisons were 
performed using the chi square test. Relationships between variables were determined using 
Spearman correlation analysis and are reported as Spearman ρ (r) values. Multivariate linear 
regression analysis was performed using cholesterol efflux capacity (CEC) as the dependent 
variable and CVD risk factors (age, sex, fasting glucose, HOMA-IR, systolic blood pressure 
(BP), BMI, apo A-1) and psoriasis evident by skin lesions as independent variables. Sex and 
psoriasis were adjusted as dichotomous variables in the models; all other variables were 
continuous. Similar findings were revealed in independent analyses designating sex and 
psoriasis as dichotomous variables and age, BMI, fasting glucose, HOMA-IR, systolic BP, 
CEC as continuous variables. Because the magnitude of the estimates of CEC did not differ 
when fixed- and random-effects regression analyses were performed, we report β-
coefficients (β) and p-values for the fixed effects models after adjustment for CVD risk 
factors.
The relative value of the presence of psoriasis compared to elevated BMI in predicting CEC 
was determined with likelihood ratio testing applied to nested multivariate regression 
models.
Finally, because NMR spectroscopy may be more readily available than cholesterol efflux 
assays and to understand the factor with the strongest contribution to efflux levels, we 
assessed which NMR-estimate parameters best predicted CEC. Likelihood-ratio testing was 
performed in nested Tobit models to determine the incremental value of psoriasis as well as 
HDL-particle size (HDL-z), particle concentration (HDL-p), and cholesterol concentration 
(HDL-c) in estimation of CEC above and beyond traditional CVD risk factors. The 
threshold of statistical significance was p≤0.05, and all analyses were performed using 
STATA 12 (College Station, TX).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Cholesterol efflux capacity by psoriasis disease severity.
a. depicts efflux capacity by psoriasis severity as measured by percent body surface area (% 
BSA), with 15 subjects with <5% BSA affected and 29 with ≥5% BSA affected.
b. depicts efflux with psoriasis severity measured by the Psoriasis Area and Severity Index 
(PASI), with 26 subjects with PASI <6 and 18 with PASI ≥ 6.
Efflux capacity is expressed as a proportion normalized to a known pooled serum sample 
from five healthy volunteers (Mean ± SD given; p-value derived from T-test with equal 
variance)
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Table 1
General characteristics of the study groups
Parameter1 Psoriasis (n=44) Controls (n=44) p-value*
Age (years) 13.0 ± 4.3 13.0 ± 4.3 Matched
Male 19 (43%) 19 (43%) Matched
Race/Ethnicity:
Caucasian 19 (43%) 20 (45%) 0.35
African American 2 (5%) 6 (14%)
Hispanic 19 (43%) 13 (30%)
Other 4 (9%) 5 (11%)
Family history:
Diabetes 23 (52%) 11 (26%) 0.01
Hypertension 26 (59%) 9 (22%) 0.001
Dyslipidemia 15 (34%) 5 (12%) 0.01
Coronary Artery Disease/Myocardial Infarction 18 (41%) 5 (12%) 0.002
Anthropometric and Blood pressure measures:
BMI (kg/m2) 23.5 ± 6.1 21.4 ± 4 0.03
BMI percentile 72 ± 28 67 ± 25 0.8
Waist circumference (cm) 80.5 ± 17.9 74.3 ± 12.5 0.04
Waist-to-hip ratio 0.85 ± 0.06 0.80 ± 0.06 <0.001
Systolic BP (mm Hg) 116 ± 11 116 ± 15 0.57
Diastolic BP (mm Hg) 63 ± 9 66 ± 9 0.1
Systolic BP percentile 68 ± 27 66 ± 29 0.64
Diastolic BP percentile 47 ± 26 54 ± 24 0.1
Psoriasis type:
Plaque 26 (59%)
Guttate 5 (11%)
Mixed lesion types 13 (30%)
Number with concomitant psoriatic arthritis Psoriasis severity: 1 (2%)
Percent Body Surface Area (% BSA), Mean (SEM) 15.7 (3.3)
 - Mild disease (<3% BSA) 11 (25%)
 - Moderate disease (3-10% BSA) 16 (36%)
 - Severe disease (>10% BSA) 17 (39%)
Psoriasis Area and Severity Index (PASI) 5.7 ± 5.2
Current treatment:
Topical therapy alone 38 (86%)
Phototherapy 0 (0%)
Systemic therapy 2 (5%)
Not on therapy 4 (9%)
Abbreviations: BMI, body mass index; BP, blood pressure
1Note: All continuous variables expressed as Mean±SD and categorical variables as N (%) unless otherwise specified
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*Simple t-test or Mann Whitney U test for continuous variables and Pearson's chi-square test for categorical variables; p≤0.05 considered 
significant
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Table 2
Lab parameters and NMR spectroscopy profile of the study groups
Parameter2 Psoriasis (n=44) Controls (n=44) p-value#
Labs:
CRP (mg/L) 0.24 ± 0.71 0.02 ± 0.11 0.02
Homocystine (μmol/L) 7.0 ± 1.9 7.4 ± 2.5 0.77
Metabolic assessment:
Insulin (mU/ml) 11.8 ± 8.9 9.8 ± 6.6 0.11
Glucose (mg/dl) 79.5 ± 7.8 80.1 ± 8.1 0.63
HOMA-IR 2.41 ± 1.83 1.99 ± 1.38 0.11
log Transformed HOMA-IR 0.65 ± 0.68 0.41 ± 0.88 0.07
Lipid profile: (mg/dl)
Total cholesterol 168.8 ± 34.3 161.1 ± 29.9 0.13
LDL-c 102.3 ± 29.6 93.8 ± 24.6 0.33
HDL-c 49.5 ± 13.4 50.4 ± 10.3 0.65
Triglycerides 88.4 ± 32.7 84.9 ± 38.6 0.33
Cholesterol: HDL-c ratio 3.6 ± 1.0 3.3 ± 0.8 0.25
Apolipoprotein A 140.3 ± 24.7 135.2 ± 17.6 0.13
Apolipoprotein B 72.4 ± 18.1 64.6 ± 16.2 0.02
NMR spectroscopy:
 VLDL Particle (VLDL-p) concn., nmol/L
 Total VLDL-p 44.4 ± 13.8 45.6 ± 21.8 0.38
 Small VLDL-p 31.2 ± 10.4 33.3 ± 15.7 0.76
 Medium VLDL-p 11.5 ± 6.3 10.7 ± 7.6 0.29
 Large VLDL-p 2.4 ± 1.4 2.4 ± 2.3 0.45
 LDL Particle (LDL-p) concn., nmol/L
 Total LDL-p 690.3 ± 287.5 662.1 ± 244.2 0.69
 Small LDL-p 228.5 ± 162 239 ± 136.2 0.63
 Large LDL-p 153.9 ± 120 136.5 ± 110.5 0.75
 HDL Particle (HDL-p) concn., μmol/L
 Total HDL-p 30.6 ± 4.5 31.1 ± 4.8 0.71
 Small HDL-p 13.4 ± 5.2 12.3 ± 4.3 0.13
 Medium HDL-p 10.5 ± 4.4 10.6 ± 6.2 0.52
 Large HDL-p 5.3 ± 2.9 6.7 ± 2.5 <0.01
 Mean Particle Size (-z), nm
 VLDL-z 47.0 ± 4.2 46.9 ± 5.4 0.45
 LDL-z 20.7 ± 0.5 20.7 ± 0.6 0.55
 HDL-z 9.4 ± 0.5 9.6 ± 0.4 0.02
Cholesterol efflux capacity: 0.90± 0.15 0.95± 0.12 0.02
NMR= Nuclear Magnetic Resonance; CRP= C-reactive protein; TNF=Tumor Necrosis Factor; HOMA-IR=Homeostasis Assessment of Insulin 
Resistance; LDL= Low-density lipoprotein; HDL= High-density lipoprotein; VLDL=Very low-density lipoprotein; IDL= Intermediate density 
lipoprotein; concn=concentration.
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2Note: All continuous variables expressed as Mean±SD
#p-value derived from simple t-test or Mann Whitney U tests; p≤0.05 considered significant
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Table 3
Regression analysis of the association of psoriasis with cholesterol efflux capacity, with 
adjustment for cardiometabolic variables
Covariates Beta p-value
Modela −0.29 0.004
Modela + HDL-c −0.22 0.021
Modela + HDL-z −0.19 0.047
Modela + HDL-p −0.25 0.013
Modela - Adjusted for age, sex, fasting glucose, HOMA-IR, Systolic BP, BMI & apolipoprotein A.
Note: Beta=Standardized regression coefficient; p≤0.05 considered significant
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Table 4
Relative value of the presence of psoriasis and elevated body mass index in predicting 
cholesterol efflux capacity
Nested models* χ2 p-value
Psoriasis added to modelb 9.12 0.003
Obesity added to modelb 0.45 0.5
Overweight-obese added to modelb 0.49 0.48
Psoriasis added to obesity in modelb 8.68 0.003
Obesity added to Psoriasis in modelb 0.02 0.89
Psoriasis added to overweight-obese in modelb 8.63 0.003
Overweight-obese added to Psoriasis in modelb 0.01 0.94
Modelb - Age, sex, fasting glucose, HOMA-IR, Systolic BP, LDL, & apolipoprotein A;
*
Likelihood ratio testing was applied to nested multivariate regression models to assess the incremental value of psoriasis and obesity in predicting 
cholesterol efflux capacity; p≤0.05 considered significant.
Obesity defined as body mass index (BMI) ≥ 95th percentile, Overweight-obese defined as BMI ≥ 85th percentile
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Table 5
Relative value of HDL-particle size, HDL-particle number and HDL cholesterol 
concentration in predicting cholesterol efflux capacity
Nested models* χ2 p-value
HDL-p added to modela 6.43 0.01
HDL-c added to modela 37.19 <0.0001
HDL-z added to modela 19.72 <0.0001
HDL-c added to HDL-z in modela 2.42 0.12
HDL-z added to HDL-c in modela 19.89 <0.0001
HDL-p added to HDL-z in modela 16.46 0.0001
HDL-z added to HDL-p in modela 29.76 <0.0001
HDL-p added to HDL-c in modela 0.31 0.58
HDL-c added to HDL-p in modela 31.08 <0.0001
Modela - Age, sex, fasting glucose, HOMA-IR, Systolic BP, BMI & apolipoprotein A.
*
Likelihood ratio testing was applied to nested multivariate regression models to assess the incremental value of HDL-z, HDL-p and HDL-c in 
predicting cholesterol efflux capacity; p≤0.05 considered significant.
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